← Leaderboards
Donald Durden Durden
Children'S Hospital Los Angeles
$10,014,138
Attributed
$10,014,138
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $965.6K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$7,914,138 · 9
FDA$2,100,000 · 2
By mechanism
R01$8,401,604 · 5
R41$508,739 · 2
P01$454,653 · 2
R21$425,500 · 1
R56$223,642 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorLaboratoriesAngiogenesisRegulationMalignant NeoplasmsSignal PathwayIn VivoInnovationClinical TrialsSignal Transduction1-Phosphatidylinositol 3-KinaseMutationIntegrinsPathway InteractionsGrowthSmall MoleculeMolecularMouse ModelCollaborationsKinase InhibitorInhibitor/AntagonistTumor GrowthCellsAdult
Grant awards (37)
Dual PI3K/BRD4 Inhibitory Chemotype for Maximum Inhibition of MYC and Cancer$390,037
R01 · FY2023 · CA · contact PI
Role of PTEN and PI-3 Kinase in Medulloblastomagenesis$309,307
R01 · FY2023 · CA · contact PI
Dual PI3K/BRD4 Inhibitory Chemotype for Maximum Inhibition of MYC and Cancer$457,586
R01 · FY2022 · CA · contact PI
Role of PTEN and PI-3 Kinase in Medulloblastomagenesis$309,307
R01 · FY2022 · CA · contact PI
Dual PI3K/BRD4 Inhibitory Chemotype for Maximum Inhibition of MYC and Cancer$1
R01 · FY2021 · CA · contact PI
Dual PI3K/BRD4 Inhibitory Chemotype for Maximum Inhibition of MYC and Cancer$487,106
R01 · FY2020 · CA · contact PI
Dual PI3K/BRD4 inhibitory chemotype for maximum inhibition of Myc and cancer$482,409
R01 · FY2019 · CA · contact PI
Role of PTEN and PI-3 Kinase in Medulloblastomagenesis$301,211
R01 · FY2019 · CA · contact PI
Dual PI3K/BRD4 inhibitory chemotype for maximum inhibition of Myc and cancer$509,469
R01 · FY2018 · CA · contact PI
Role of PTEN and PI-3 kinase in medulloblastomagenesis$315,619
R01 · FY2018 · CA · contact PI
Phase 2 Study of Poly-ICLC in the Treatment of Pediatric Low Grade Gliomas$400,000
R01 · FY2017 · FD · contact PI
Role of PTEN and PI-3 kinase in medulloblastomagenesis$315,619
R01 · FY2017 · CA · contact PI
A Phase I study of a dual PI3K/BRD4 inhibitor, SF1126 in the treatment of hepatocellular carcinoma IDE: 74,551$250,000
R01 · FY2017 · FD · contact PI
Phase 2 Study of Poly-ICLC in the Treatment of Pediatric Low Grade Gliomas$400,000
R01 · FY2016 · FD · contact PI
Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors$299,738
R41 · FY2016 · CA · contact PI
A Phase I study of a dual PI3K/BRD4 inhibitor, SF1126 in the treatment of hepatocellular carcinoma | IDE: 74,551$250,000
R01 · FY2016 · FD · contact PI
Phase 2 Study of Poly-ICLC in the Treatment of Pediatric Low Grade Gliomas$400,000
R01 · FY2015 · FD · contact PI
Maximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitors$209,001
R41 · FY2015 · CA · contact PI
Phase 2 Study of Poly-ICLC in the Treatment of Pediatric Low Grade Gliomas$400,000
R01 · FY2014 · FD · contact PI
Vascular targeted pan PI-3 kinase inhibitor prodrug, SF1126 for glioma therapy$268,308
R01 · FY2012 · CA · contact PI
Vascular targeted pan PI-3 kinase inhibitor prodrug, SF1126 for glioma therapy$268,308
R01 · FY2011 · CA · contact PI
Vascular targeted pan PI-3 kinase inhibitor prodrug, SF1126 for glioma therapy$276,606
R01 · FY2010 · CA · contact PI
Role of Syk and Rac2 in regulation of HIF1alpha and neovascularization.$231,750
R21 · FY2010 · HL · contact PI
Vascular targeted pan PI-3 kinase inhibitor prodrug, SF1126 for glioma therapy$277,501
R01 · FY2009 · CA · contact PI
Role of Syk and Rac2 in regulation of HIF1alpha and neovascularization.$144,412
R21 · FY2009 · HL · contact PI
Role of Syk and Rac2 in regulation of HIF1alpha and neovascularization.$49,338
R21 · FY2009 · HL · contact PI
Vascular targeted pan PI-3kinase inhibitor prodrug, SF1126 for glioma therapy.$223,642
R56 · FY2008 · CA · contact PI
PTEN/AKTp53 signaling axis in tumor induced angiogenesis$265,940
R01 · FY2006 · CA · contact PI
Rac2 in integrin macrophage function$237,288
P01 · FY2006 · HL · contact PI
PTEN/AKTp53 signaling axis in tumor induced angiogenesis$272,340
R01 · FY2005 · CA
PTEN/AKTp53 signaling axis in tumor induced angiogenesis$272,340
R01 · FY2004 · CA
PTEN/AKTp53 signaling axis in tumor induced angiogenesis$257,370
R01 · FY2003 · CA
PTEN/AKTp53 signaling axis in tumor induced angiogenesis$265,220
R01 · FY2002 · CA
Rac2 in integrin macrophage function$217,365
P01 · FY2002 · HL
Vascular endothelial cell integrins in angiogenesis$0
P01 · FY2002 · CA
Vascular endothelial cell integrins in angiogenesis$0
P01 · FY2001 · CA
Vascular endothelial cell integrins in angiogenesis$0
P01 · FY2000 · CA